Which Head and Neck Cancer Patients Are Most at Risk of High Levels of Fear of Cancer Recurrence by Rogers, SN et al.
ORIGINAL RESEARCH
published: 16 July 2021
doi: 10.3389/fpsyg.2021.671366






Paul Van De Heyning,
University of Antwerp, Belgium
Seockhoon Chung,










This article was submitted to
Psycho-Oncology,
a section of the journal
Frontiers in Psychology
Received: 23 February 2021
Accepted: 07 June 2021
Published: 16 July 2021
Citation:
Rogers SN, Monssen C,
Humphris GM, Lowe D and Kanatas A
(2021) Which Head and Neck Cancer
Patients Are Most at Risk of High
Levels of Fear of Cancer Recurrence.
Front. Psychol. 12:671366.
doi: 10.3389/fpsyg.2021.671366
Which Head and Neck Cancer
Patients Are Most at Risk of High
Levels of Fear of Cancer Recurrence
Simon N. Rogers 1,2*†, Camilla Monssen 3, Gerald M. Humphris 3, Derek Lowe 4 and
Anastasios Kanatas 5†
1 Faculty of Health and Social Care, Edge Hill University, Ormskirk, United Kingdom, 2 Liverpool Head and Neck Centre,
Liverpool University Hospital Aintree, Liverpool, United Kingdom, 3 School of Medicine, Medical and Biological Sciences,
North Haugh, St. Andrews, United Kingdom, 4 Astraglobe Ltd., Congleton, United Kingdom, 5 Leeds Teaching Hospitals and
St. James Institute of Oncology, Leeds Dental Institute and Leeds General Infirmary, Leeds, United Kingdom
Background: Fear of cancer recurrence (FCR) is recognized as a common concern for
patients with head and neck cancer (HNC). The aim of this study is to describe in greater
detail the demographic and clinical characteristics of HCN patients who indicate a high
level of FCR in their review consultation.
Methods: A pragmatic cluster-controlled trial was conducted between January 2017
and December 2018 at two UK HNC centers (Leeds and Liverpool) to test the efficacy
of a prompt tool called the Patient Concerns Inventory (PCI). Patients completed the
PCI and the UW-QOLv4 which included a single 5 category rating of FCR. Secondary
statistical analyses focused on variables associated with high FCR.
Results: Two hundred and eighty-eight trial patients were recruited in this trial. At
a median of 194 days after diagnosis and 103 days after the end of treatment 8%
stated (n = 24) “I get a lot of fears of recurrence and these can really preoccupy my
thoughts” and 3% (n = 8) “I am fearful all the time that my cancer might return, and I
struggle with this.” Thus, 11% (n = 32) responded in the worst two categories, 95%
Confidence interval 7.7–15.3% for high FCR. Stepwise logistic regression resulted in
female gender (p < 0.001), age (p = 0.007), and receiving financial benefits (p = 0.01)
as independent predictors.
Conclusions: Around one in ten HNC patients attending routine outpatient follow-up
consultations report high FCR, however for female patients under the age of 55 the rate
was one in three. This group requires specialist attention and could be the focus of a
multicenter intervention trial.
Keywords: fear of cancer recurrence, quality of life, patient concerns inventory, head and neck cancer, randomized
trial
INTRODUCTION
Head and neck cancer (HNC) is the eighth most commonly diagnosed cancer in the UK (Cancer
Research UK, 2017) with approximately 12,200 new cases each year. Risk factors include smoking
and alcohol and recently the Human Papilloma virus (HPV) (Cooper et al., 2009; Dhull et al., 2018).
The 5-year disease specific survival is around 60% for both men and women (Cadoni et al., 2017).
Most HNC recurrences occur within the first 2 years following diagnosis (Kissun et al., 2006) and
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have a poor prognosis with survival in terms ofmonths (Fullarton
et al., 2016). With this backdrop it is hardly surprising that
Fear of Cancer Recurrence (FCR) is (Humphris and Ozakinci,
2008) one of the most frequent issues patients wish to talk about
in their out-patient review consultations (Kanatas et al., 2012).
Given the likelihood of early recurrence, clinicians often stress
the importance of vigilance and adherence to follow-up visits.
One of the greatest challenges is carefully balancing the degree
of emphasis on recurrence without alarming the patient. Fear
of Cancer Recurrence is of particular interest as this fear holds
considerable psychological stress which in turn negatively affects
the patient’s quality of life (QoL) (Smith et al., 2006; Dunne et al.,
2017), daily functioning (Lee-Jones et al., 1997), relationship with
carers (Hodges and Humphris, 2009), and mental well-being
(Humphris et al., 2003). HNC survivors with inadequate health
literacy have increased FCR compared to those with adequate
health literacy (Clarke et al., 2021).
The issue of FCR can be hard to elicit in the follow-up
clinic, whether this be face to face or virtual, as imposed
by restrictions due to the COVID-19 pandemic. The Patients
Concerns Inventory (PCI) is a condition specific prompt list
devised in collaboration with patients as a means by which they
can raise issues of concern with the clinician (Rogers et al., 2009)
(Supplementary Material). A systematic review and content
comparison of unmet needs self-report measures favored the
PCI over 13 other tools (Shunmugasundaram et al., 2019). In
a randomized trial the PCI has been shown to be a low-cost
intervention which is feasible in routine clinical practice and is
associated with a positive effect on QoL and socio-emotional
dysfunction (Rogers et al., 2020).
Although the PCI can help to identify the frequency of FCR
(Rogers et al., 2010a; Kanatas et al., 2012; Ghazali et al., 2013),
thus far specific details of which kind of patient is most at risk are
lacking. The PCI randomized trial (Rogers et al., 2020) has given
an opportunity to evaluate in much greater depth the issue of
FCR and this is of particular merit as the trial is based in standard
practice and involved 15 consultant HNC surgeons. Hence, the
aim of this study is to describe the demographic background and
clinical characteristics for those HCN patients who indicate a
high level of FCR in their review consultation. This may allow
prompt identification of those patients in need of further support
during their clinical consultations.
MATERIALS AND METHODS
Setting and Participants
Themethodology of this trial has been described in detail (Rogers
et al., 2018a). Briefly, this is a pragmatic cluster-controlled trial,
with consultants (clusters) randomized to “using” or “not using”
an intervention incorporating the PCI prompt list at all their
trial clinics, i.e., at both baseline and at all follow-up clinics. Two
centers participated, Aintree and Leeds, with 15 consultants of
whom 8 used the PCI and 7 did not. We report results from
the first “baseline” trial clinic and focus on findings regarding
fear of recurrence (FCR). We also report FCR results after 12
months of follow-up. Eligible patients were treated curatively
for primary HNC, and all sites, stages of disease and treatments
were included, and second primary tumors were later accepted.
Patients treated palliatively or with a recurrence or with a history
of cognitive impairment, psychoses or dementia were excluded.
Measures
The UW-QOL v4 questionnaire comprises 12 single item
domains, with between 3 and 5 response options scaled
evenly from 0 (worst) to 100 (best) according to response
hierarchy (Rogers et al., 2002). UW-QOL domains are presented
within two subscales, physical function and social-emotional
function (Rogers et al., 2010b) with each subscale score being
the mean of six domain scores (http://www.hancsupport.
com/professionals/quality-life/qol-questionnaires/university-
washington). The physical function score is the mean of the
appearance, swallowing, chewing, speech, taste and saliva
domain scores, while the social-emotional score is the mean
of the pain, activity, recreation, shoulder, mood, and anxiety
domain scores. Criteria derived from earlier work was used to
highlight domains in which patients have a significant problem
or dysfunction (Rogers and Lowe, 2009). There was also a single
item overall QOL question on the UWQOL v4 for which patients
are asked to consider not only physical and mental health, but
also other factors, such as family, friends, spirituality, or personal
leisure activities important to their enjoyment of life. The study
HRQOL data also included the Distress Thermometer score
(Hegel et al., 2008) and EQ-5D-5L (Rogers et al., 2016).
The FCR question has five response options: (A) I have no fear
of recurrence, (B) I have a little fear, with occasional thoughts
but they don’t really bother me, (C) I am sometimes having
fearful thoughts, but I can usually manage these, (D) I get a lot of
fears of recurrence and these can really preoccupy my thoughts,
(E) I am fearful all the time that my cancer might return and
I struggle with this. There is also a separate question asking
patients whether FCR had been important to them (Yes/No)
during the past 7 days. From earlier work (Rogers et al., 2016)
it was postulated that those patients responding in the worst
two categories should be considered for added assessment and
support; we define these patients as having a significant problem
or dysfunction with FCR.
The PCI is a condition-specific item prompt list (Rogers et al.,
2009) comprising 56 items, which patients select from before
seeing their consultant, to help guide the outpatient consultation,
and it covers a range of symptoms and potential problems
patients may face after treatment. It helps focus the consultation,
aids doctor–patient communication, and helps route patients to
other professionals for advice and support. It can be integrated
into routine clinical practice (Rogers et al., 2018b).
Pre-consultation questionnaires including the PCI prompt list
were completed electronically (desktop, tablet, iPAD) apart from
one Liverpool hospital (non-PCI consultant) that used paper.
PCI patients took into their consultations a summary sheet of
paper that listed (a) all PCI items they selected for discussion, (b)
any University ofWashington (UWQOL) questionnaire domains
in which there was a significant problem or dysfunction, (c)
their overall QOL response, (d) their Distress Thermometer
score, and (e) health professionals they wanted to see. This
one page paper summary printout was the visible difference
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between trial arms as far as contact between consultant and
patient was concerned. Control patients completed exactly the
same pre-clinic information apart from the PCI prompt list
but neither they nor their consultant saw any summary sheet.
Both groups completed the EQ-5D-5L for purposes of health
economic assessment.
Baseline clinical and demographic data were collected using
a baseline clinic questionnaire based on that of the Head and
Neck 5000 project (Ness et al., 2014), or by extraction from
baseline clinical records. Information was collected as to whether
patients lived alone or with others, whether they were working
and whether they lived in a household that received UK state
financial benefits. Lifestyle factors about tobacco and alcohol
use were also collected, as was patient gender and age. Clinical
details about primary tumor site, grade, treatment, WHO, and
ACE27 comorbidity were obtained from clinical records. Index
of Multiple Deprivation (English Indices of Deprivation–IMD,
2019) scores were derived from patient postcodes using publicly
available data and these provide a relative measure of deprivation
at a small area level across England.
Statistical Analyses
The statistical analysis focused on variables associated with
FCR dysfunction. We considered patient and clinical casemix
variables and also a wide range of HRQOL measures. Fishers
Exact test was used to compare patient groups regarding FCR
dysfunction (Yes/No). Logistic regression was used to form
predictive models of FCR dysfunction. Univariate models with
each predictor variable were run and the Nagelkerke R square
value (R2) was noted for each model, these values providing
an indication of which models better predict FCR dysfunction;
the higher the value the better the prediction. Multivariable
logistic regressionmodeling was done using significant univariate
casemix variables (Table 1) and a stepwise regression approach
with p < 0.01 for inclusion was adopted for the consideration
of the many HRQOL predictor variables (Table 2). Given the
number of tests performed for this paper, statistical significance
was regarded as p < 0.01.
RESULTS
Patients for the trial were first discussed at MDT meetings
between January 2017 and December 2018, with first trial clinics
between April 2017 and October 2019. Characteristics of the
288 trial patients can be determined from Table 1. Median
(IQR) age at baseline was 62 (55–69) and 69% (198) were male.
Baseline clinics were a median (IQR) of 194 (125–249) days
after diagnosis and 103 (71–162) days after the end of treatment.
Regarding FCR, 15% (43) stated “I have no fear of recurrence,”
44% (127) “I have a little fear, with occasional thoughts but
they don’t really bother me,” 30% (86) “I am sometimes having
fearful thoughts but I can usually manage these,” 8% (24) “I
get a lot of fears of recurrence and these can really preoccupy
my thoughts,” and 3% (8) “I am fearful all the time that my
cancer might return and I struggle with this.” Thus 11% (32)
responded in the worst two categories, 95% Confidence interval
7.7–15.3% for FCR dysfunction, and this rate was notably higher
in females and in patients younger than 65 years (Table 1). No
significant variation was seen regarding tumor site, clinical stage,
or treatment. It was also higher in those still smoking and in those
with households receiving financial benefits. Stepwise logistic
regression with gender, age (<55/55–64/≥65), financial benefits
(Yes/No), and smoking habit (Current/Ex/Never) resulted in
gender (p < 0.001), age (p = 0.007), and financial benefits (p =
0.01) as independent predictors, n= 265. The first two predictors,
gender and age, were retained to preserve the full sample size.
In female patients under the age of 55 the rate was 36% (10/28),
while for those aged 55–64 it was 29% (8/28) and for those ≥65
it was 3% (1/34); for males the rates were 12% (5/43), 7% (6/88),
and 3% (2/67), respectively.
Most of the HRQOL measures in this study were associated
with FCR (Table 2) and with each other (results not shown).
Fear of Cancer Recurrence dysfunction was present in 49%
(24/49) of those with dysfunction in anxiety (UWQOL), in
47% (21/45) of those with dysfunction in mood (UWQOL), in
44% (21/48) with moderate, severe, or extreme problems with
anxiety/depression (EQ5D), in 43% (10/23) with dysfunction in
recreation (UWQOL) and 42% (11/26) with poor or very poor
overall quality of file (UWQOL). Comparison of the R2 values
indicated that the most predictive variables from Table 2 were
UWQOL anxiety (R2 = 41.1), EQ5D anxiety/depression (37.0),
UWQOL Mood (31.2) and UWQOL social-emotional function
subscale score (26.9). In comparison the R2-value for the model
with gender and age group was 18.2. When gender and age and
all the variables from Table 2 were considered within a stepwise
regression at p < 0.001 for entry then UWQOL anxiety (p <
0.001, R2 = 41.1) was selected first, followed by UWQOL Mood
(p < 0.001, R2 = 46.4 combined) and then gender (p = 0.002,
R2 = 52.1 combined). If patients had both UWQOL anxiety and
mood dysfunction then 66% (19/29) also had FCR dysfunction
(males: 61%, 11/18; females: 73%, 8/11). If patients had UWQOL
anxiety and mood dysfunction but not both then 19% (7/36) had
FCR dysfunction (males; 9%, 2/22; females: 36%, 5/14). For other
patients only 3% (6/223) had FCR dysfunction (males: 0%, 0/158;
females: 9%, 6/65).
One-third (97/288) of patients said that FCR had been
important to them in the past week, and this varied from 81%
(26/32) of those with FCR dysfunction, 50% (43/86) of those
sometimes having fearful thoughts, 19% (24/127) of those having
a little fear and 9% (4/43) of those without fear at the time of
data entry. In the group who sometimes had fearful thoughts,
there were no significant differences in patient characteristics
between the 43 patients regarding FCR as important and the
43 patients for whom it was not important (Tables 1, 2) apart
from an association with EQ5D anxiety/depression (p < 0.001)
in Table 2 which only affected the balance between not being
anxious or depressed and being slightly anxious or depressed.
Patients in the PCI intervention group could select the FCR item
from the PCI prompt list if they wanted to discuss this during
their consultation, and 34% (48/140) did select this item. Of the
16 patients with FCR dysfunction then 8 wanted to discuss their
fears and 8 did not (Table 3). About half (53%, 23/43) of patients
who sometimes had fearful thoughts but could usually manage
them wanted to discuss their fears, 74% (14/19) if FCR had been
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TABLE 1 | Patient and clinical characteristics and fear of recurrence.
Fear of recurrence response category* % with FCR
dysfunction (A&B)
P-value*** R2-value****
Patients A&B) C+ C– D E
Total 288 32 43 43 127 43 11
Trial group PCI 140 16 19 24 62 19 11 >0.99 <0.1
Non-PCI 148 16 24 19 65 24 11
Hospital Aintree 178 19 30 26 76 27 11 0.85 0.1
Leeds 110 13 13 17 51 16 12
Days from diagnosis to
first clinic (TERTILES)
≤144 96 12 14 14 39 17 13 0.60
125–227 96 8 15 18 41 14 8 0.8
≥228 96 12 14 11 47 12 13
Days from end of
treatment to first clinic
(TERTILES)
≤79 96 13 13 16 37 17 14 0.29 1.8
80–138 98 7 16 15 47 13 7
≥139 94 12 14 12 43 13 13
Duration of consultation
(min) TERTILES
≤8min 92 7 9 13 38 25 8 1.8
9–12min 103 10 17 16 47 13 10 0.32
≥13min 88 13 17 14 39 5 15
Gender Female 90 19 18 16 26 11 21 0.001 8.3
Male 198 13 25 27 101 32 7
Age <55 71 15 12 13 27 4 21 0.002 10.3 (<55,
55–64, ≥65)
55–64 116 14 19 18 50 15 12
65–74 67 3 7 10 35 12 4
≥75 34 0 5 2 15 12 0
Tumor site: Oral cavity 134 18 18 23 57 18 13 0.77 1.0
Oropharynx 91 8 20 12 37 14 9
Larynx 41 4 3 4 21 9 10
Other 22 2 2 4 12 2 9
Overall clinical stage Advanced 3–4 164 18 29 26 71 20 11 >0.99 <0.1
Early 1–2 124 14 14 17 56 23 11
Primary treatment**: S only 95 12 9 10 44 20 13 0.93
S only and FF 21 1 5 4 8 3 5
RT or RT/CT only 58 7 11 11 24 5 12 1.0
S and (RT or RT/CT) 68 7 13 9 31 8 10
S and (RT or RT/CT)
and FF
46 5 5 9 20 7 11
WHO comorbidity 0 179 15 31 27 82 24 8 0.10
1 67 9 6 11 32 9 13 2.8
2–4 42 8 6 5 13 10 19
ACE27 comorbidity None 137 15 23 20 59 20 11 0.50 1.1
Mild 95 11 14 13 43 14 12
Moderate 48 4 6 8 22 8 8
Severe 8 2 0 2 3 1 25
Living situation Alone in house/flat 65 4 8 7 29 17 6 0.26
With others in
house/flat
220 27 35 36 97 25 12 1.5
Working Yes 88 7 15 9 46 11 8 0.31 0.9
No 192 24 27 31 79 31 13
(Continued)
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TABLE 1 | Continued
Fear of recurrence response category* % with FCR
dysfunction (A&B)
P-value*** R2-value****
Patients A&B) C+ C– D E
Financial (household)
benefits
Yes 107 17 14 18 44 14 16 0.01 4.8
No 158 10 26 20 77 25 6
Smoking habit Current 37 9 2 11 10 5 24 0.009
Former 163 19 27 22 72 23 12 6.1
Never 80 4 13 9 41 13 5
Alcohol habit Current 194 20 26 29 89 30 10 0.65
Former 73 9 13 11 31 9 12 0.3
Never 13 2 3 2 3 3 15
IMD 2019 quintile 1 = least deprived 34 3 7 5 14 5 9 0.73
2 55 4 13 7 20 11 7
3 49 5 7 8 23 6 10 1.7
4 40 4 4 4 24 4 10
5 = most deprived 110 16 12 19 46 17 15
*(A), I have no fear of recurrence; (B), I have a little fear, with occasional thoughts but they don’t really bother me; (C+), I am sometimes having fearful thoughts but I can usually manage
these, and important during the past 7 days; (C–), I am sometimes having fearful thoughts but I can usually manage these and NOT important during the past 7 days; (D), I get a lot of
fears of recurrence and these can really preoccupy my thoughts; (E), I am fearful all the time that my cancer might return and I struggle with this.
**Surgery (S), RadioTherapy (RT), ChemoTherapy (CT), Free Flap transfer (FF).
***Fishers Exact test.
****Nagelkerke R2-value provides an indication of which models better predict FCR dysfunction; the higher the value the better the prediction.
important to them during the past week and 38% (9/24) if FCR
had not been not important. About one quarter (27%, 17/62)
with just a little fear wanted to discuss FCR, 56% (5/9) if FCR
had been important, and 23% (12/53) if not important. None
of the 19 patients without FCR wanted to discuss the issue. Of
those wanting to discuss their fears, most (40/48) did not have
FCR dysfunction.
During the trial patients attended a median (IQR) of 4 (3–5)
clinics, range 1–10. Follow-up results at around 12 months were
available for 205 patients, at a median (IQR) of 357 (329–391)
days from baseline. The percentages with FCR dysfunction were
8% (17/205) at the first study clinic and 6% (13/205) after about
12months. Five patients had FCR dysfunction on both occasions,
12 only at first, 8 only later, and 180 on neither occasion. In female
patients under the age of 65 the rates for FCR dysfunction were
25% (10/40) and 13% (5/40), while for older females they were
0% (0/22) and 5% (1/22); for males 6% (6/96), 7% (7/96), and 2%
(1/47), 0% (0/47), respectively. Of 83 lost to the study between
baseline and follow-up, 18% (15) had significant fears at the first
clinic. The FCR item from the PCI prompt list was selected by
36% (36/100) at baseline and 17% (17/100) at follow-up.
DISCUSSION
Fear of Cancer Recurrence is an issue that is common in HNC
and one that is amenable to intervention (Humphris and Rogers,
2012). Its prevalence rate overall was in the region of one in
ten patients and this is similar to previous studies (Llewellyn
et al., 2008). A more recent survey in the Netherlands using
the Cancer Worry Scale has reported “approximately one in
two of all patients newly diagnosed with HNC had FCR levels
above the validated cut-off for high FCR shortly after diagnosis
(Mirosevic et al., 2019).” There may be differences with the
proportion of patients categorized as stating they have high FCR
according to the measure employed. For example, the Mirosevic
et al. article (Mirosevic et al., 2019) set their cut-off against the
validated Fears of Cancer Recurrence Inventory (FCRI). A review
of the FCRI has raised concerns about the low cut-off on this
measure (Smith et al., 2020). Hence, careful attention needs to
be paid to the actual wording and psychometric properties of the
measures used. Our single item follows the principles of keeping
the assessment of FCR focused and with face valid wording,
expressed by Costa (2017). Furthermore, our group subscribe to
the view that moderate levels of FCR are probably of value, and
not regarded as dysfunctional, as the patient remains reasonably
vigilant to changes to symptom experience. The caveat would
be for patients to have the support from the H&N team should
these fears become heightened, and maintained, and for the staff
to monitor and discuss their FCR to reverse back to a moderate
level. Among the variables that clinicians can use to identify
patients with H&N cancer and high FCR indicated by this data
set, include the following:
Age
A significant relationship between the younger age of these
patients and dysfunctional FCR was found. This was 21% in
those under 55, 14% in those aged 55–64 and only 3% in
those over 65. The median age in this study was 62 implying
that nearly half of the patient population is at higher risk.
This association is in line with previous research indicating
Frontiers in Psychology | www.frontiersin.org 5 July 2021 | Volume 12 | Article 671366
Rogers et al. Fear of Cancer Recurrence
TABLE 2 | HRQOL measures and fear of recurrence.
Fear of recurrence response category* % with FCR
dysfunction (A&B)
P-value*** R2-value****
Patients A&B) C+ C– D E
Total 288 32 43 43 127 43 11
UWQOL Overall Quality
of life
Outstanding/Very good 105 4 9 12 58 22 4 <0.001 16.1
Good 94 9 20 12 41 12 10
Fair 63 8 11 15 23 6 13
Very Poor/Poor 26 11 3 4 5 3 42
Distress thermometer
(DT)
Zero 79 0 3 4 46 26 0 <0.001 17.5 (0–3, 4–5,
6–10)
1–3 80 5 14 13 39 9 6
4–5 60 9 12 7 27 5 15




<60 72 24 14 16 17 1 33 <0.001 26.7
60–79 98 5 18 18 46 11 5
80–100 118 3 11 9 64 31 3
UWQOL physical
function subscale
<60 91 20 18 18 27 8 22 0.001
60–79 108 8 14 17 53 16 7 10.4
80–100 89 4 11 8 47 19 4
Social-emotional
subscale
• Pain Best possible response 108 8 12 7 56 25 7 0.20
Somewhere
in-between
97 11 14 22 37 13 11 2.2
Dysfunction 83 13 17 14 34 5 16
• Activity Best possible response 86 3 7 9 46 21 3 <0.001
Somewhere
in-between
168 19 31 25 74 19 11 10.2
Dysfunction 34 10 5 9 7 3 29
• Recreation Best possible response 109 8 9 10 58 24 7 <0.001
Somewhere
in-between
156 14 28 32 64 18 9 12.1
Dysfunction 23 10 6 1 5 1 43
• Shoulder Best possible response 160 6 25 26 73 30 4 <0.001
Somewhere
in-between
92 18 14 13 38 9 20 13.8
Dysfunction 36 8 4 4 16 4 22
• Mood Best possible response 97 0 4 6 58 29 0 <0.001
Somewhere
in-between
146 11 34 26 63 12 8 31.2
(dysfunction,
other)
Dysfunction 45 21 5 11 6 2 47
• Anxiety Best possible response 103 1 2 4 56 40 1 <0.001
Somewhere
in-between
136 7 28 31 68 2 5 41.1
Dysfunction 49 24 13 8 3 1 49
Physical function
subscale
• Appearance Best possible response 75 3 10 9 30 23 4 0.003
Somewhere
in-between
185 21 28 28 91 17 11 7.7
(Continued)
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TABLE 2 | Continued
Fear of recurrence response category* % with FCR
dysfunction (A&B)
P-value*** R2-value****
Patients A&B) C+ C– D E
Dysfunction 28 8 5 6 6 3 29
• Swallowing Best possible response 104 9 12 10 54 19 9 0.03
Somewhere
in-between
142 13 23 22 64 20 9 4.5
Dysfunction 42 10 8 11 9 4 24
• Chewing Best possible response 117 8 11 13 63 22 7 0.09
Somewhere
in-between
133 17 28 18 54 16 13 3.1
Dysfunction 38 7 4 12 10 5 18
• Speech Best possible response 123 11 15 13 60 24 9 0.02
Somewhere
in-between
142 14 25 24 62 17 10 4.9
Dysfunction 23 7 3 6 5 2 30
• Taste Best possible response 90 3 9 11 50 17 3 <0.001
Somewhere
in-between
141 20 23 21 59 18 14 6.6
Dysfunction 57 9 11 11 18 8 16
• Saliva Best possible response 80 3 6 7 43 21 4 0.03
Somewhere
in-between
109 14 21 17 42 15 13 5.1
Dysfunction 99 15 16 19 42 7 15
Other item:
• Intimacy Best possible response 212 13 25 26 108 40 6 <0.001
Somewhere
in-between
61 15 15 12 16 3 25 11.9
Dysfunction 15 4 3 5 3 0 27
EQ-5D
Mobility (walking about) No problems 180 12 22 23 93 30 7 0.002
Slight problems 43 5 9 6 14 9 12 7.9
Moderate/severe/unable 65 15 12 14 20 4 23
Self-care (washing or
dressing myself)
No problems 222 15 34 30 103 40 7 <0.001
Slight problems 34 5 4 5 17 3 15 13.6
Moderate/severe/unable 32 12 5 8 7 0 38
Usual activities No problems 143 9 16 16 73 29 6 0.001
Slight problems 74 6 14 13 33 8 8 9.4
Moderate/severe/unable 71 17 13 14 21 6 24
Pain (or discomfort) No pain or discomfort 104 7 10 8 52 27 7 0.04
Slight pain or
discomfort
96 9 17 17 43 10 9 4.4
Moderate/severe/extreme 88 16 16 18 32 6 18
Anxiety/Depression Not anxious or
depressed
145 1 4 19 83 38 1 <0.001
Slightly anxious or
depressed
95 10 30 14 39 2 11 37.0




≤0.6950 96 24 19 18 32 3 25 <0.001
(Continued)
Frontiers in Psychology | www.frontiersin.org 7 July 2021 | Volume 12 | Article 671366
Rogers et al. Fear of Cancer Recurrence
TABLE 2 | Continued
Fear of recurrence response category* % with FCR
dysfunction (A&B)
P-value*** R2-value****
Patients A&B) C+ C– D E
0.6951–0.8370 109 3 21 18 48 19 3 18.3
≥0.8371 83 5 3 7 47 21 6
EQ5D Visual analog
scale (VAS) TERTILES
≤69 96 19 15 20 36 6 20 0.007
70–81 96 7 23 11 37 18 7 7.1
≥82 96 6 5 12 54 19 6
*(A), I have no fear of recurrence; (B), I have a little fear, with occasional thoughts but they don’t really bother me, (C+), I am sometimes having fearful thoughts but I can usually manage
these, and important during the past 7 days, (C–), I am sometimes having fearful thoughts but I can usually manage these, and NOT important during the past 7 days, (D), I get a lot of
fears of recurrence and these can really preoccupy my thoughts, (E), I am fearful all the time that my cancer might return and I struggle with this.
*** Fishers Exact test.
**** Nagelkerke R2-value provides an indication of which models better predict FCR dysfunction; the higher the value the better the prediction.
TABLE 3 | Selection of FCR item from the PCI prompt list for 140 PCI patients, by self-reported level of fear of recurrence (FCR) and by whether FCR had been important
over the past 7 days.
Single FCR question FCR item selected from PCI prompt list FCR important in the
past 7 days
FCR item selected from PCI prompt list
% Patients % Patients
I am fearful all the time that my cancer might
return and I struggle with this
50 8/16 Yes 57 8/14
I get a lot of fears of recurrence and these
can really preoccupy my thoughts
No 0 0/2
I am sometimes having fearful thoughts but I
can usually manage these
53 23/43 Yes 74 14/19
No 38 9/24
I have a little fear, with occasional thoughts
but they don’t really bother me
27 17/62 Yes 56 5/9
No 23 12/53
I have no fear of recurrence 0 0/19 Yes 0 0/1
No 0 0/18
Total 34 48/140 Yes 63 27/43
No 22 21/97
age was a predictor of FCR (Humphris et al., 2003; Lim and
Humphris, 2020). There are several potential explanations as to
why age plays a significant role in fears of recurrence. Researchers
(Hutton and Williams, 2001) have argued that older patients
are not always able to differentiate the interference caused by
treatment and the natural degeneration of aging, with a cancer
diagnosis becoming increasingly more predictable with older age.
In comparison, younger patients find the diagnoses of cancer
much more unanticipated and abrupt as it threatens their ability
to fulfill major life events, such as having grandchildren or
marriage of children (Simard et al., 2013).
Gender
The finding that gender is associated with FCR has been
highlighted in a recent systematic review (Pang and Humphris,
2021). One explanation as to why females experience higher
FCR is because they tend to experience more symptoms of
dysfunctional anxiety (Faravelli et al., 2013). A Norwegian and
Swedish HNC study found that those who were under 65 and
female were the most likely to develop anxiety (Hammerlid
et al., 1999). In this analysis’ parent study, 17% of patients
experienced dysfunctional anxiety symptoms according to the
UWQOL social-emotional subscale. As anxiety levels were not
included in their secondary analysis, we must leave room to
consider whether present FCR are a surface level manifestation of
other psychiatric comorbidities that have been previously found
to be significant within this sub-population.
Financial Benefits
In this study, it was found that a significant predictor of
developing FCR was living in a household in receipt of financial
benefits. Head and neck cancer has a serious impact on patient
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finances and is associated with poor HRQOL (Rogers et al.,
2012). Previous evidence has shown that rates of financial
instability are the highest within HNC in comparison to all
other cancer types (Avis et al., 2005). This is exemplified within
this study with 37% of participants in households receiving
financial benefits. A systematic review of FCR found that of
the 10 studies investigating financial difficulties and FCR, the
association was only found to be significant in three (Simard
et al., 2013). However, previous studies regarding FCR and
financial position should be applied carefully as this fear could be
more prominent in countries whose national health programme
relies solely on private hospitals. In a previous study within
our group, it was found that FCR had a weak relationship with
deprivation which would partially support this finding of patients
reporting to receive state benefits (Rylands et al., 2016). This
mirrors the findings of a study by Clarke et al. (2021) in which
HNC survivors with inadequate health literacy reported lower
levels of self-management behaviors, lower functional HRQOL,
and increased FCR.
Health Related Quality of Life
Functional/symptom items on H&N cancer HRQOL
questionnaires have potential utility in respect to FCR as
symptoms that patients experience might trigger anxiety
regarding the possibility of recurrence. This is especially so in
the field of H&N cancer care where previous reports of patient
experience of physical symptoms have focused our group to
build on the FCR model proposed by Lee-Jones et al. (1997) and
promoted the AFTER intervention (Humphris and Ozakinci,
2008) to reduce high FCR. Most of the HRQOL measures in
this study were associated with FCR, for example, 42% in those
with poor or very poor overall QOL had dysfunctional FCR.
There was anxiety or mood dysfunction in 65 patients (23% of
the whole sample) and this group accounted for 81% (26/32)
of all those with FCR dysfunction. These relatively broad-brush
HRQOL questionnaires, such as the UW-QOL mood and
anxiety items and, interestingly a similar amount of variance
explained with another well-developed measure, namely: the
EQ-5D, together with the EORTCc30, these assessments have
shown the ability to identify patients with high FCR. Due to
the high degree of overlap between these HRQOL measures,
only one or, at most, two would be required to assist with
identifying patients with possible high FCR. Within England
the NHS England QOL Metric study outcome measures include
the EQ-5D and EORTCc30 (NHS England Cancer Data, 2021).
Hence, it would enable all cancer patients in England to be given
the opportunity to complete the questionnaires at the 18 month
post diagnosis window. Those scoring badly, for example, on
the EQ-5D will have possibly high FCR which would need to
be further assessed. These assessment approaches are part of a
possible development to construct stepped-care programmes
of support and intervention for moderate to high scorers
of FCR which is being explored in patients with melanoma
(Lynch et al., 2020).
The regression R2-values (Table 2) indicated that the age
and gender associations with FCR were dwarfed relatively
by the associations between the HRQOL measures and FCR.
Logistic regression on FCR using all variables in Table 2 as
predictors selected anxiety, mood, and gender. For patients with
anxiety or mood dysfunction or both—there was dysfunctional
FCR for 56% of females (13/25) and 32% (13/40) of males;
for patients without anxiety of mood dysfunction—there was
dysfunctional FCR for 9% (6/65) of females and 0% (0/158)
of males.
Our results have included a split of the FCR patient responses
to the middle category of the rating scale. The split was whether,
or not, FCR had been “important” to the patient within the
previous 7 days. We found on close inspection little difference
about this split—in either patient/clinical characteristics or across
the HRQOL measures. Hence the important message that this
reinforces is that dysfunction in FCR is best measured by the
worst two FCR response options only and that the middle option
if important should not be added to this. This recommendation
was postulated in a previous paper (Rogers et al., 2016). In
addition, it is worth emphasizing that a degree of FCR is “normal”
and to be expected. In our sample, three quarters reported “I have
a little fear, with occasional thoughts but they don’t really bother
me” (44%) and “I am sometimes having fearful thoughts but I can
usually manage these” (30%).
Exploring the longitudinal data, FCR severe rates remain
relatively unchanged over the year with evidence of a slight
improvement 8–6%. This serves to highlight how imbeded this
fear can be for patients. Patients still wish to talk about FCR
involving one in three at the start of the trial and one in five
at the last consultation. The PCI prompt is potentially a useful
adjunct to the conversation with the health professional as even
with the passage of time it helps the patients to broach what
can be a sensitive and distressing issue and this provides an
opportunity to reassure on repeated occasions as prompted by
the patient themselves.
There are several potential limitations of this work. Firstly,
in the trial of those approached to be recruited, around one
in five declined to participate. It might be that patients with
an anxiety disorder are less likely to take part and that
these are more likely to experience high FCR. Thus, this
current analysis might underestimate the rates of FCR. The
findings should have a reasonable level of generalisability, as
although involving only two centers, 15 different consultants
were involved, and the sample comprised 80% of eligible
patients. The second limitation relates to the single FCR item
question used as part of the HRQOL survey. It is recognized
that this question will not be as reliable as other more
comprehensive FCR measures (Thewes et al., 2012). However,
this together with the PCI item on FCR gives a unique
opportunity to analyse characteristics that might be predictive
of higher FCR dysfunction. Because of the variety of different
criteria and definitions of FCR, direct comparisons to this
research with other studies should be treated with caution
(Mirosevic et al., 2019). This should also be considered in any
future work.
The potential value of using a prompt list (PCI) as part of
the consultation is that patients might be more amenable to
raise the FCR issue through this prompt, and also to discuss
their fear in preference to discussing other psychological issues
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such as depression or anxiety. Fear of Cancer Recurrence is
perceived as an understandable concern that both the patient and
the clinician can relate to. When talking through natural and
health concerns the clinician can gauge the extent of the fear and
can offer additional support. A specific FCR intervention could
be considered for those most distressed. Considerable work is
now being conducted to develop interventions for those with
high levels of FCR (Tauber et al., 2019). Further research is
needed to carefully construct and evaluate the cost effectiveness
of a tiered programme of support. However, a straightforward
means to highlight the issue of FCR in routine oncology clinics,
either by clinical characteristics, questionnaire caseness, or a
prompt from the patient themselves, or a combination of these,
could be a suitable starting point for both informal and formal
Interventions, with the desired outcome being less distress and
improved HRQOL.
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